Research progress on criteria for discontinuation of EGFR inhibitor therapy

References

• MendelsohnJBaselgaJStatus of epidermal growth factor receptor antagonists in the biology and treatment of cancerJ Clin Oncol200321142787279912860957
   PubMed Web of Science ®Google Scholar
• YaishPGazitAGilonCLevitzkiABlocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitorsScience198824248809339353263702
   PubMed Web of Science ®Google Scholar
• GschwindAFischerOMUllrichAThe discovery of receptor tyrosine kinases: targets for cancer therapyNat Rev Cancer20044536137015122207
   PubMed Web of Science ®Google Scholar
• BaselgaJCortesJEpidermal growth factor receptor pathway inhibitorsCancer Chemother Biol Response Modif200522120522316110613
   PubMedGoogle Scholar
• LeszczynieckaMRobertsTDentPGrantSFisherPBDifferentiation therapy of human cancer: basic science and clinical applicationsPharmacol Ther2001902–310515611578655
   PubMed Web of Science ®Google Scholar
• ZhuZTargeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectivesActa Pharmacol Sin20072891476149317723181
   PubMed Web of Science ®Google Scholar
• CiardielloFTortoraGA novel approach in the treatment of cancer: targeting the epidermal growth factor receptorClin Cancer Res20017102958297011595683
   PubMed Web of Science ®Google Scholar
• HarariPMEpidermal growth factor receptor inhibition strategies in oncologyEndocr Relat Cancer200411468970815613446
   PubMed Web of Science ®Google Scholar
• DassonvilleOBozecAFischelJLMilanoGEGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differencesCrit Rev Oncol Hematol2007621536117324578
   PubMed Web of Science ®Google Scholar
• KrisMGNataleRBHerbstRSEfficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trialJAMA2003290162149215814570950
   PubMed Web of Science ®Google Scholar
• FukuokaMYanoSGiacconeGMulti-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial) [corrected]J Clin Oncol200321232237224612748244
   PubMed Web of Science ®Google Scholar
• BonnerJAHarariPMGiraltJRadiotherapy plus cetuximab for squamous-cell carcinoma of the head and neckN Engl J Med2006354656757816467544
   PubMed Web of Science ®Google Scholar
• CunninghamDHumbletYSienaSCetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancerN Engl J Med2004351433734515269313
   PubMed Web of Science ®Google Scholar
• Haas-KoganDAPradosMDTihanTEpidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinibJ Natl Cancer Inst2005971288088715956649
   PubMed Web of Science ®Google Scholar
• MellinghoffIKWangMYVivancoIMolecular determinants of the response of glioblastomas to EGFR kinase inhibitorsN Engl J Med2005353192012202416282176
   PubMed Web of Science ®Google Scholar
• BarberTDVogelsteinBKinzlerKWVelculescuVESomatic mutations of EGFR in colorectal cancers and glioblastomasN Engl J Med200435127288315625347
   PubMed Web of Science ®Google Scholar
• MarieYCarpentierAFOmuroAMEGFR tyrosine kinase domain mutations in human gliomasNeurology20056481444144515851741
   PubMed Web of Science ®Google Scholar
• MontagutCSettlemanJTargeting the RAF-MEK-ERK pathway in cancer therapyCancer Lett2009283212513419217204
   PubMed Web of Science ®Google Scholar
• MendelsohnJBaselgaJEpidermal growth factor receptor targeting in cancerSemin Oncol200633436938516890793
   PubMed Web of Science ®Google Scholar
• PaoWMillerVAKrisMG“Targeting” the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC)Semin Cancer Biol2004141334014757534
   PubMed Web of Science ®Google Scholar
• JimenoAHidalgoMPharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitorsBiochim Biophys Acta20061766221722917045403
   PubMed Web of Science ®Google Scholar
• Di MaioMGridelliCNormannoNPerroneFCiardielloFTrying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancerJ Cell Physiol2005205335536315895392
   PubMed Web of Science ®Google Scholar
• HussainSAPalmerDHSpoonerDReaDWMolecularly targeted therapeutics for breast cancerBiodrugs200721421522417628119
   PubMed Web of Science ®Google Scholar
• MorgilloFLeeHYResistance to epidermal growth factor receptor-targeted therapyDrug Resist Updat20058529831016172017
   PubMed Web of Science ®Google Scholar
• RieseDNSternDFSpecificity within the EGF family/ErbB receptor family signaling networkBioessays199820141489504046
   PubMed Web of Science ®Google Scholar
• DentPReardonDBParkJSRadiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell deathMol Biol Cell19991082493250610436007
   PubMed Web of Science ®Google Scholar
• DongJWileyHSTrafficking and proteolytic release of epidermal growth factor receptor ligands are modulated by their membrane-anchoring domainsJ Biol Chem2000275155756410617651
   PubMed Web of Science ®Google Scholar
• FanHDerynckREctodomain shedding of TGF-alpha and other transmembrane proteins is induced by receptor tyrosine kinase activation and MAP kinase signaling cascadesEMBO J199918246962697210601018
   PubMed Web of Science ®Google Scholar
• RoudabushFLPierceKLMaudsleySKhanKDLuttrellLMTransactivation of the EGF receptor mediates IGF-1-stimulated Shc phosphorylation and ERK1/2 activation in COS-7 cellsJ Biol Chem200027529225832258910807918
   PubMed Web of Science ®Google Scholar
• WakelingAEGuySPWoodburnJRZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapyCancer Res200262205749575412384534
   PubMed Web of Science ®Google Scholar
• LiuBFangMLuYMendelsohnJFanZFibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibodyOncogene200120151913192211313939
   PubMed Web of Science ®Google Scholar
• MotoyamaABHynesNELaneHAThe efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptidesCancer Res200262113151315812036928
   PubMed Web of Science ®Google Scholar
• Ferrer-SolerLVazquez-MartinABrunetJMenendezJADe LlorensRColomerRAn update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: gefitinib (Iressa)-induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligandsInt J Mol Med200720131017549382
   PubMed Web of Science ®Google Scholar
• WikstrandCJReistCJArcherGEZalutskyMRBignerDDThe class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic targetJ Neurovirol1998421481589584952
   PubMed Web of Science ®Google Scholar
• LearnCAHartzellTLWikstrandCJResistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiformeClin Cancer Res20041093216312415131063
   PubMed Web of Science ®Google Scholar
• LiBYuanMKimIAChangCMBernhardEJShuHKMutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic originOncogene200423264594460215077177
   PubMed Web of Science ®Google Scholar
• LynchTJBellDWSordellaRActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med2004350212129213915118073
   PubMed Web of Science ®Google Scholar
• PaezJGJannePALeeJCEGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyScience200430456761497150015118125
   PubMed Web of Science ®Google Scholar
• YunCHMengwasserKETomsAVThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPProc Natl Acad Sci U S A200810562070207518227510
   PubMed Web of Science ®Google Scholar
• PaoWWangTYRielyGJKRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinibPLoS Med200521e1715696205
   PubMed Web of Science ®Google Scholar
• BeanJBrennanCShihJYMET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibProc Natl Acad Sci U S A200710452209322093718093943
   PubMed Web of Science ®Google Scholar
• SchmidtLDuhFMChenFGermline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomasNat Genet199716168739140397
   PubMed Web of Science ®Google Scholar
• SmolenGASordellaRMuirBAmplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752Proc Natl Acad Sci U S A200610372316232116461907
   PubMed Web of Science ®Google Scholar
• EngelmanJAZejnullahuKMitsudomiTMET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalingScience200731658271039104317463250
   PubMed Web of Science ®Google Scholar
• YamamotoHToyookaSMitsudomiTImpact of EGFR mutation analysis in non-small cell lung cancerLung Cancer200963331532118760859
   PubMed Web of Science ®Google Scholar
• JanmaatMLKruytFARodriguezJAGiacconeGResponse to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathwaysClin Cancer Res2003962316232612796401
   PubMed Web of Science ®Google Scholar
• WymannMPPirolaLStructure and function of phosphoinositide 3-kinasesBiochim Biophys Acta199814361/21271509838078
   PubMed Web of Science ®Google Scholar
• KolchWCalderMGilbertDWhen kinases meet mathematics: the systems biology of MAPK signallingFEBS Lett200557981891189515763569
   PubMed Web of Science ®Google Scholar
• GilmoreAPValentijnAJWangPActivation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptorJ Biol Chem200227731276432765012011069
   PubMed Web of Science ®Google Scholar
• LiBChangCMYuanMMcKennaWGShuHKResistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomasCancer Res200363217443745014612544
   PubMed Web of Science ®Google Scholar
• BusseDDoughtyRSRamseyTTReversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activityJ Biol Chem2000275106987699510702262
   PubMed Web of Science ®Google Scholar
• KoizumiFShimoyamaTTaguchiFSaijoNNishioKEstablishment of a human non-small cell lung cancer cell line resistant to gefitinibInt J Cancer20051161364415761868
   PubMed Web of Science ®Google Scholar
• BiancoRShinIRitterCALoss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitorsOncogene200322182812282212743604
   PubMed Web of Science ®Google Scholar
• PilotoOWrightMBrownPKimKTLevisMSmallDProlonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathwaysBlood200710941643165217047150
   PubMed Web of Science ®Google Scholar
• ChakravartiALoefflerJSDysonNJInsulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signalingCancer Res200262120020711782378
   PubMed Web of Science ®Google Scholar
• UllrichAGrayATamAWInsulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificityEMBO J1986510250325122877871
   PubMed Web of Science ®Google Scholar
• SasakiTKnyazevPGCloutNJStructural basis for Gas6-Axl signallingEMBO J2006251808716362042
   PubMed Web of Science ®Google Scholar
• JinQEstevaFJCross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancerJ Mammary Gland Biol Neoplasia200813448549819034632
   PubMed Web of Science ®Google Scholar
• HendricksonAWHaluskaPResistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapyCurr Opin Investig Drugs2009101010321040
   Google Scholar
• JonesHEGoddardLGeeJMInsulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cellsEndocr Relat Cancer200411479381415613453
   PubMed Web of Science ®Google Scholar
• GschwindAZwickEPrenzelNLesererMUllrichACell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmissionOncogene200120131594160011313906
   PubMed Web of Science ®Google Scholar
• PierceKLLuttrellLMLefkowitzRJNew mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascadesOncogene200120131532153911313899
   PubMed Web of Science ®Google Scholar
• MarinissenMJGutkindJSG-protein-coupled receptors and signaling networks: emerging paradigmsTrends Pharmacol Sci200122736837611431032
   PubMed Web of Science ®Google Scholar
• AhmadTFarnieGBundredNJAndersonNGThe mitogenic action of insulin-like growth factor I in normal human mammary epithelial cells requires the epidermal growth factor receptor tyrosine kinaseJ Biol Chem200427931713171914593113
   PubMed Web of Science ®Google Scholar
• GelmonKAMackeyJVermaSUse of trastuzumab beyond disease progression: observations from a retrospective review of case historiesClin Breast Cancer200451525815140285
   PubMedGoogle Scholar
• MontemurroFValabregaGAgliettaMTrastuzumab-based combination therapy for breast cancerExpert Opin Pharmacother200451819614680438
   PubMed Web of Science ®Google Scholar
• TripathyDSlamonDJCobleighMSafety of treatment of metastatic breast cancer with trastuzumab beyond disease progressionJ Clin Oncol20042261063107015020607
   PubMed Web of Science ®Google Scholar
• RielyGJKrisMGZhaoBProspective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimusClin Cancer Res200713175150515517785570
   PubMed Web of Science ®Google Scholar
• RielyGJPaoWPhamDClinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinibClin Cancer Res2006123 Pt 183984416467097
   PubMed Web of Science ®Google Scholar
• JackmanDMYeapBYSequistLVExon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinibClin Cancer Res200612133908391416818686
   PubMed Web of Science ®Google Scholar
• KwakELSordellaRBellDWIrreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinibProc Natl Acad Sci U S A2005102217665767015897464
   PubMed Web of Science ®Google Scholar
• EngelmanJAMukoharaTZejnullahuKAllelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancerJ Clin Invest2006116102695270616906227
   PubMed Web of Science ®Google Scholar
• OnitsukaTUramotoHNoseNAcquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF statusLung Cancer201068219820319589612
   PubMed Web of Science ®Google Scholar
• CiardielloFTortoraGEGFR antagonists in cancer treatmentN Engl J Med2008358111160117418337605
   PubMed Web of Science ®Google Scholar
• HopfnerMHuetherASutterAPBaradariVSchuppanDScherublHBlockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cellsBiochem Pharmacol200671101435144816530734
   PubMed Web of Science ®Google Scholar
• Aviel-RonenSBlackhallFHShepherdFATsaoMSK-ras mutations in non-small-cell lung carcinoma: a reviewClin Lung Cancer200681303816870043
   PubMed Web of Science ®Google Scholar
• BarnesCJOhshiroKRayalaSKEl-NaggarAKKumarRInsulin-like growth factor receptor as a therapeutic target in head and neck cancerClin Cancer Res200713144291429917634559
   PubMed Web of Science ®Google Scholar
• MellinghoffIKCloughesyTFMischelPSPTEN-mediated resistance to epidermal growth factor receptor kinase inhibitorsClin Cancer Res2007132 Pt 137838117255257
   PubMed Web of Science ®Google Scholar
• Di MarioAGarziaMD’AloFRapid leukaemic evolution in a cutaneous blastic NK-cell lymphoma initially diagnosed as pseudolymphomaHematology200712215515717454197
   PubMed Web of Science ®Google Scholar
• KamathSBuolamwiniJKTargeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and developmentMed Res Rev200626556959416788977
   PubMed Web of Science ®Google Scholar
• Perez-SolerRHER1/EGFR targeting: refining the strategyOncologist200491586714755015
   PubMed Web of Science ®Google Scholar